Table 1.
No. | Study | Country | Total of samples | Agec | Diagnostic tool | |
---|---|---|---|---|---|---|
ADHD | Control | |||||
1 | Aarts et al. [12] | Netherlands | 19 ADHD, 77 controlsa | 19.5 | 27.1 | K-SADS based on DSM-IV |
2 | Jiang et al. [9] | China (Zhejiang) | 51 ADHD, 32 controls | 8.47 | 8.5 | K-SADS-PL based on DSM-IV |
3 | Prehn-Kristensen et al. [14] | Germany | 14 ADHDb, 17 controlsb | 11.9 | 13.1 | K-SADS-PL (Germany translation) based on DSM-IV |
4 | Wang et al. [10] | China (Taiwan) | 30 ADHD, 30 controls | 8.4 | 9.3 | K-SADS-E (China version) based on DSM-IV-TR |
5 | Wan et al. [11] | China (Beijing) | 17 ADHD, 17 controls | 8 (median) | 8 (median) | K-SADS based on DSM-5 |
6 | Szopinska-Tokov et al. [13] | Netherlands | 41 ADHD, 15 subthreshold ADHD, 47 controls | ADHD = 20,2; subthreshold ADHD = 20,2 | 20.5 | K-SADS based on DSM-IV |
aControl samples consists of 17 healthy participants, 21 healthy siblings of ADHD patients, and 39 self-reported healthy participants diagnosed by Brain Imaging Genetics (BIG)
bAll the samples are from male participants. ADHD samples consists of 12 participants with combination type and 2 participants with inattention; 6 patients out of 14 have ODD comorbidities; and 10 patients had been consuming ADHD medication for more than a year to treat ADHD (nine of them had agreed to stop the consumption 48 h prior to samples collection)
cThe data are displayed in mean